Skip to main content

Table 1 Parameters in control and omarigliptin group with NAFLD at baseline and 12 months

From: Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Time (month)

Control (n = 12)

Omarigliptin (n = 21)

0

12

0

12

HbA1c

6.83 ± 0.69

6.80 ± 0.63

6.91 ± 0.73

6.80 ± 0.71

BMI

26.5 ± 2.4

26.7 ± 2.1

26.6 ± 2.7

26.5 ± 2.7

ALT

30.8 ± 19.5

32.4 ± 28.4

30.1 ± 20.5

25.2 ± 14.4 *

AST

35.1 ± 8.4

37.5 ± 10.0

34.8 ± 11.6

30.0 ± 8.6 *

γGTP

38.5 ± 6.6

39.0 ± 5.5

43.8 ± 29.6

32.7 ± 19.8 *

hsCRP

0.130 ± 0.04

0.151 ± 0.06

0.105 ± 0.05

0.042 ± 0.02 **

HOMA-IR

2.83 ± 0.79

2.72 ± 0.82

2.75 ± 1.28

1.85 ± 0.88 **

  1. Data were expressed as mean ± standard deviation. (*p < 0.05, **p < 0.01)
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us